Report Library

Reports

Pulmonary alveolar proteinosis (PAP) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Prevalence has been reported to be from 3.7 to 40 cases per million depending on the country. The incidence has been estimated to be 0.2 cases per million. Autoimmune PAP accounts for approximately 90% of cases, while 4% is secondary PAP, 1% is congenital PAP, and undetermined PAP-like disease represents the remaining 5%. Smoking is reported in 53% to 85% of PAP patients.


Published:2021-01-14   Updated:2021-05-17        Pages:186   
Complex regional pain syndrome (CRPS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

CRPS occurs most frequently in people of European ancestry (in about 66 to 80 percent of cases). In a study done in the United States, it was found that CRPS type I developed in 5.46 persons out of every 100,000 per year. It is estimated that CRPS affects nearly 200,000 patients annually in the United States.


Published:2020-10-06   Updated:2021-04-02        Pages:191   
Spinocerebellar ataxia (SCA) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

It is estimated that 150,000 people in the United States are affected by, or at risk for, spinocerebellar ataxia (hereditary ataxia).  Some ataxias are more common in certain ethnic groups. For example, SCA3 is more common in the Portuguese population, SCA10 is more common in the Mexican population, and DRPLA is more common in Japan.


Published:2020-10-22   Updated:2021-05-10        Pages:245   
Clostridioides difficile infection (CDI) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

The overall age and sex adjusted CDI incidence in the USA was ranges between 143.5 to 157.8 cases per 100,000 populations. There were 345K to 356K CDI-related hospitalizations being reported in 2019. This accounted for 0.9% to 1.21% of all hospitalizations in the year. Out of these hospitalizations, 29.3% had CDI as a principal diagnosis and 70.7% of the hospitalizations had CDI as a secondary diagnosis. Epidemiology section of the study provides a Comprehensive insight on patient segmentation based on age, sex, Type of settings; Chronic and recurrent CDI, Severity (Mild, Moderate, Severe), Risk factors (Drug induced, CKD, diabetes mellitus, lymphoma or leukemia, or Solid tumors, IBD, CHF, COPD, Ulcer, GERD, and others) in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China


Published:2021-01-04   Updated:2021-04-12        Pages:244